LP
AVIR icon

LMR Partners’s Atea Pharmaceuticals AVIR Stock Holding History

LMR Partners’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,595
Closed -$138K – 1028
2022
Q4 		$138K Sell
28,595
-4,957
-15% -$25.1K ﹤0.01% 1022
2022
Q3 		$191K Sell
33,552
-35,267
-51% -$270K ﹤0.01% 1020
2022
Q2 		$489K Buy
68,819
+40,148
+140% +$274K 0.01% 933
2022
Q1 		$207K Buy
+28,671
New +$195K ﹤0.01% 1136

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's AVIR Position: Q1 2023 in Review

LMR Partners sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 28,595 shares — an estimated $138K sold.

LMR Partners first reported a position in AVIR in Q1 2022 and held it in 4 quarters. The position peaked at $489K in Q2 2022. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

  • LMR Partners reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • LMR Partners sold 28,595 Atea Pharmaceuticals shares in Q1 2023, an estimated $138K.
  • LMR Partners first reported a position in Atea Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • LMR Partners's Atea Pharmaceuticals position peaked at $489K in Q2 2022.
  • 130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on LMR Partners's 13F filing for Q1 2023, filed 15 May 2023.